Bausch + Lomb ELIOS Glaucoma Data Bolsters US Market Entry Hopes
Event summary
- Bausch + Lomb released positive 24-month data from a U.S. clinical trial for its ELIOS glaucoma treatment system.
- The trial, involving 318 patients, demonstrated a 76% achievement of at least a 20% reduction in IOP and an average IOP reduction of 7.4 mmHg.
- 82% of patients were medication-free at 23 months following the ELIOS procedure.
- The ELIOS system, already CE marked in Europe, uses excimer laser technology for an implant-free glaucoma treatment.
The big picture
The ELIOS system represents Bausch + Lomb's strategic push into the US minimally invasive glaucoma surgery (MIGS) market, which has seen significant growth in Europe. The positive trial data provides a strong foundation for FDA approval, but the company faces competition from established players and the need to educate US clinicians on the benefits of this implant-free laser technology. Success hinges on navigating the regulatory process and driving adoption among specialists.
What we're watching
- Regulatory Approval
- The FDA review process will be critical; a protracted or negative review could significantly delay US market entry and impact investor sentiment.
- Adoption Rate
- The speed at which ophthalmologists and cataract specialists adopt the ELIOS procedure in the US will determine its commercial success, particularly given existing MIGS alternatives.
- Competitive Landscape
- Bausch + Lomb will need to demonstrate a clear advantage over existing minimally invasive glaucoma surgery (MIGS) options to gain meaningful market share.
Related topics